Compass Pathways plc Depositary Receipt

Compass Pathways plc Depositary Receipt represents shares in Compass Pathways plc, a biotechnology company focused on mental health innovation in the United Kingdom and the United States. The company develops COMP360, a proprietary investigational formulation of synthetic psilocybin therapy administered with psychological support, currently advancing through Phase III clinical trials for treatment-resistant depression. It is also in Phase II trials for post-traumatic stress disorder and anorexia nervosa. Compass Pathways plc pioneers a novel treatment model aimed at addressing unmet needs in mental health care for patients unresponsive to existing therapies. Its pipeline emphasizes evidence-based psychedelic-assisted therapies to improve outcomes in severe psychiatric conditions. Founded in 2020 and headquartered in London, United Kingdom, the company plays a significant role in the emerging field of psychedelic medicine development.